{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:50:08Z","timestamp":1794329408125,"version":"4.9.0"},"reference-count":336,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00908-0","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:47:20Z","timestamp":1772441240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective"],"prefix":"10.1186","volume":"14","author":[{"given":"Jiahui","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengming","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"6330","key":"908_CR1","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152\u201358.","journal-title":"Science"},{"issue":"12","key":"908_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18(12):773\u201391.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"908_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cmet.2012.06.016","volume":"16","author":"P Bai","year":"2012","unstructured":"Bai P, Cant\u00f3 C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab. 2012;16(3):290\u201395.","journal-title":"Cell Metab"},{"issue":"2","key":"908_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.molcel.2018.06.004","volume":"71","author":"H Hanzlikova","year":"2018","unstructured":"Hanzlikova H, Kalasova I, Demin AA, Pennicott LE, Cihlarova Z, Caldecott KW. The importance of Poly(hypenCapswithspaceRetainColl1ibose) polymerase as a sensor of unligated Okazaki fragments during DNA replication. Mol Cell. 2018;71(2):319\u201331.","journal-title":"Mol Cell"},{"issue":"10","key":"908_CR5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"908_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/jpm10020041","volume":"10","author":"S Boussios","year":"2020","unstructured":"Boussios S, Mikropoulos C, Samartzis E, Karihtala P, Moschetta M, Sheriff M, et al. Wise management of ovarian cancer: on the cutting Edge. J Pers Med. 2020;10(2):41.","journal-title":"J Pers Med"},{"issue":"2","key":"908_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","volume":"108","author":"AR Venkitaraman","year":"2002","unstructured":"Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171\u201382.","journal-title":"Cell"},{"issue":"10","key":"908_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A. Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer. 2004;4(10):814\u201319.","journal-title":"Nat Rev Cancer"},{"key":"908_CR9","doi-asserted-by":"crossref","unstructured":"Li X, Zou L. Brcaness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality. J Clin Invest. 2024;134(14):e181062.","DOI":"10.1172\/JCI181062"},{"issue":"12","key":"908_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","volume":"61","author":"MAC Bruin","year":"2022","unstructured":"Bruin MAC, Sonke GS, Beijnen JH, Huitema ADR. Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin Pharmacokinet. 2022;61(12):1649\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"908_CR11","first-page":"141","volume":"75","author":"C Hage Chehade","year":"2025","unstructured":"Hage Chehade C, Gebrael G, Sayegh N, Ozay ZI, Narang A, Crispino T, et al. A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin. 2025;75(2):141\u201367.","journal-title":"CA Cancer J Clin"},{"key":"908_CR12","unstructured":"Breast Cancer Study Locator. PETRA: study of AZD5305 as monotherapy and in combination with anti-cancer agents in patients with advanced solid malignancies. 2025. https:\/\/www.breastcancerstudylocator.com\/trial\/listing\/260668. Accessed 5 Feb 2026."},{"issue":"4_suppl","key":"908_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.2024.42.4_suppl.123","volume":"42","author":"A Azad","year":"2024","unstructured":"Azad A, Voskoboynik M, Joshua AM, Weickhardt AJ, Sankey P, Pacey S, et al. PETRANHA: phase 1\/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer-interim safety and pharmacokinetic results. J Clin Oncol. 2024;42(4_suppl):123.","journal-title":"J Clin Oncol"},{"key":"908_CR14","unstructured":"UroToday. First interim efficacy analysis of the phase 1\/2 PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC). 2025. https:\/\/www.urotoday.com\/conference-highlights\/esmo-2025\/esmo-2025-prostate-cancer\/164003-esmo-2025-first-interim-efficacy-analysis-of-the-phase-1-2-petranha-trial-of-saruparib-androgen-receptor-pathway-inhibitors-arpi-in-patients-pts-with-metastatic-prostate-cancer-mpc.html. Accessed 5 Feb 2026."},{"key":"908_CR15","unstructured":"U. EvoPAR-Prostate01: phase III, double-blind, placebo-controlled, 2-Cohort, randomized study of saruparib in combination with androgen receptor pathway inhibitors in patients with mHSPC with and without homologous recombination repair mutation. 2025. https:\/\/www.urotoday.com\/conference-highlights\/asco-gu-2025\/asco-gu-2025-prostate-cancer\/158429-asco-gu-2025-evopar-prostate01-phase-iii-double-blind-placebo-controlled-2-cohort-randomized-study-of-saruparib-in-combination-with-androgen-receptor-pathway-inhibitors-in-patients-with-mhspc-with-and-without-homologous-recombination-repair-mutation.html. Accessed 5 Feb 2026."},{"key":"908_CR16","doi-asserted-by":"crossref","unstructured":"Razavi P, Balma\u00f1a J, Luen SJ, Campone M, Cortesi L, Masuda N, et al. Abstract P2-10-17. A randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4\/6i plus physician\u2019s choice endocrine therapy or + camizestrant in patients w\/BRCA1\/BRCA2\/PALB2 mutations & HR+\/HER2- advanced breast cancer (EvoPAR-Breast01). Clin Cancer Res. 2025;31(12_Supplement):P2\u201310\u20137.","DOI":"10.1158\/1557-3265.SABCS24-P2-10-17"},{"issue":"6","key":"908_CR17","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-024-03003-9","volume":"30","author":"X Wu","year":"2024","unstructured":"Wu X, Liu J, Wang J, Wang L, Lin Z, Wang X, et al. Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial. Nat Med. 2024;30(6):1612\u201321.","journal-title":"Nat Med"},{"key":"908_CR18","doi-asserted-by":"crossref","unstructured":"Cao J, Guo H, Ji D, Shen W, Zhang S, Hsieh CY, et al. Safety, tolerability, and pharmacokinetics of senaparib, a novel PARP1\/2 inhibitor, in Chinese patients with advanced solid tumors: a phase I trial. Oncologist. 2023;28(12):e1259\u201367.","DOI":"10.1093\/oncolo\/oyad163"},{"issue":"7","key":"908_CR19","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/cncr.34662","volume":"129","author":"B Gao","year":"2023","unstructured":"Gao B, Voskoboynik M, Cooper A, Wilkinson K, Hoon S, Hsieh CY, et al. A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors. Cancer. 2023;129(7):1041\u201350.","journal-title":"Cancer"},{"key":"908_CR20","unstructured":"ClinicalTrials.gov. Study of AZD9574 as monotherapy and in combination with anti-cancer agents in participants with advanced solid malignancies (CERTIS1). 2026. https:\/\/clinicaltrials.gov\/study\/NCT05417594. Accessed 5 Feb 2026."},{"issue":"22","key":"908_CR21","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.21.01511","volume":"40","author":"N Li","year":"2022","unstructured":"Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, et al. Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. J Clin Oncol. 2022;40(22):2436\u201346.","journal-title":"J Clin Oncol"},{"issue":"9","key":"908_CR22","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-20-3546","volume":"27","author":"N Li","year":"2021","unstructured":"Li N, Bu H, Liu J, Zhu J, Zhou Q, Wang L, et al. An open-label, multicenter, single-arm, phase II study of fluzoparib in patients with germline BRCA1\/2 mutation and platinum-sensitive recurrent ovarian cancer. Clin Cancer Res. 2021;27(9):2452\u201358.","journal-title":"Clin Cancer Res"},{"key":"908_CR23","doi-asserted-by":"crossref","unstructured":"Li N, Wu L, Wang J, Li Q, Wang D, Tang J, et al. 1063O Fuzuloparib (FZPL) monotherapy or in combination with apatinib (APA) as first-line (1L) maintenance therapy in advanced ovarian cancer (OC): final analysis of the FZOCUS-1 trial. Ann Oncol. 2025;36:S712.","DOI":"10.1016\/j.annonc.2025.08.1703"},{"issue":"6","key":"908_CR24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.annonc.2024.04.003","volume":"35","author":"H Li","year":"2024","unstructured":"Li H, Liu J, Liu Y, Ouyang Q, Wang S, Tong Z, et al. VP2-2024: fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1\/2 mutations (gBRCA1\/2m): a randomized phase III trial. Ann Oncol. 2024;35(6):574\u201375.","journal-title":"Ann Oncol"},{"issue":"3","key":"908_CR25","doi-asserted-by":"publisher","first-page":"102018","DOI":"10.1016\/j.xcrm.2025.102018","volume":"6","author":"T Zhang","year":"2025","unstructured":"Zhang T, Wang B, Wei Y, Gan H, Fang B, Li X, et al. Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): a single-arm phase 2 study. Cell Rep Med. 2025;6(3):102018.","journal-title":"Cell Rep. Med"},{"issue":"4","key":"908_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41416-020-0916-5","volume":"123","author":"R Plummer","year":"2020","unstructured":"Plummer R, Dua D, Cresti N, Drew Y, Stephens P, Foegh M, et al. First-in-human study of the PARP\/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor. Br J Cancer. 2020;123(4):525\u201333.","journal-title":"Br J Cancer"},{"key":"908_CR27","unstructured":"ClinicalTrials.gov. Investigation of the anti-tumor effect of 2X-121 in patients with recurrent, advanced ovarian cancer. 2026. https:\/\/clinicaltrials.gov\/study\/NCT03878849. Accessed 5 Feb 2026."},{"key":"908_CR28","doi-asserted-by":"crossref","unstructured":"Kim SB, Bae KS, Lee JL, Lee WS, Ock CY, Lee MJ, et al. First-in-human dose finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors. Cancer Med. 2025;14(4):e70576.","DOI":"10.1002\/cam4.70576"},{"key":"908_CR29","unstructured":"ClinicalTrials.gov. Basket trial of IDX-1197, a PARP inhibitor, in patients with HRR mutated solid tumors (VASTUS) (VASTUS). 2026. https:\/\/clinicaltrials.gov\/study\/NCT04174716. Accessed 5 Feb 2026."},{"key":"908_CR30","doi-asserted-by":"publisher","first-page":"102045","DOI":"10.1016\/j.canep.2021.102045","volume":"75","author":"N Pavlidis","year":"2021","unstructured":"Pavlidis N, Rassy E, Vermorken JB, Assi T, Kattan J, Boussios S, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021;75:102045.","journal-title":"Cancer Epidemiol"},{"issue":"13","key":"908_CR31","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.3390\/ijerph19138113","volume":"19","author":"S Shah","year":"2022","unstructured":"Shah S, Cheung A, Kutka M, Sheriff M, Boussios S. Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health. 2022;19(13):8113.","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"3","key":"908_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG, 3004 trial. J Clin Oncol. 2023;41(3):609\u201317.","journal-title":"J Clin Oncol"},{"issue":"26","key":"908_CR33","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"10106","key":"908_CR34","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949\u201361.","journal-title":"Lancet"},{"issue":"25","key":"908_CR35","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"26","key":"908_CR36","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"issue":"26","key":"908_CR37","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383.","journal-title":"N Engl J Med"},{"key":"908_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.critrevonc.2019.01.002","volume":"136","author":"C Marchetti","year":"2019","unstructured":"Marchetti C, De Felice F, Perniola G, Palaia I, Musella A, Di Donato V, et al. Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: a meta-analysis. Crit Rev Oncol Hematol. 2019;136:64\u201369.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"908_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","volume":"23","author":"R Kristeleit","year":"2022","unstructured":"Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. The Lancet Oncol. 2022;23(4):465\u201378.","journal-title":"The Lancet Oncol"},{"issue":"11","key":"908_CR40","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.19.02745","volume":"38","author":"RT Penson","year":"2020","unstructured":"Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzi\u0144ski M, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38(11):1164\u201374.","journal-title":"J Clin Oncol"},{"issue":"12","key":"908_CR41","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1200\/JCO.24.00933","volume":"43","author":"G Scambia","year":"2025","unstructured":"Scambia G, Villalobos Valencia R, Colombo N, Cibula D, Leath CA 3rd, Bidzi\u0144ski M, et al. Olaparib as treatment versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer: phase, III, SOLO3 study final overall survival results. J Clin Oncol. 2025;43(12):1408\u201316.","journal-title":"J Clin Oncol"},{"issue":"12","key":"908_CR42","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncol. 2021;22(12):1721\u201331.","journal-title":"The Lancet Oncol"},{"issue":"8","key":"908_CR43","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681\u201392.","journal-title":"Ann Oncol"},{"issue":"4","key":"908_CR44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","volume":"34","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, et al. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial. Int J Gynecol Cancer. 2024;34(4):550\u201358.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"908_CR45","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ygyno.2021.12.016","volume":"164","author":"P Harter","year":"2022","unstructured":"Harter P, Mouret-Reynier MA, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Bogner G, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial. Gynecol Oncol. 2022;164(2):254\u201364.","journal-title":"Gynecol Oncol"},{"key":"908_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","volume":"174","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2022","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, et al. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial. Eur J Cancer. 2022;174:221\u201331.","journal-title":"Eur J Cancer"},{"issue":"12","key":"908_CR47","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1136\/ijgc-2021-002933","volume":"31","author":"BJ Monk","year":"2021","unstructured":"Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, et al. ATHENA (GOG-3020\/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021;31(12):1589\u201394.","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"908_CR48","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. 2024;35(11):981\u201392.","journal-title":"Ann Oncol"},{"key":"908_CR49","doi-asserted-by":"publisher","first-page":"112908","DOI":"10.1016\/j.ejca.2023.04.024","volume":"189","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, et al. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023;189:112908.","journal-title":"Eur J Cancer"},{"issue":"25","key":"908_CR50","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"9","key":"908_CR51","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"The Lancet Oncol"},{"issue":"5","key":"908_CR52","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncol. 2021;22(5):620\u201331.","journal-title":"The Lancet Oncol"},{"issue":"22","key":"908_CR53","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"908_CR54","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"908_CR55","doi-asserted-by":"publisher","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","volume":"212","author":"AM Karim","year":"2023","unstructured":"Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, et al. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol. 2023;212:115545.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"908_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40364-024-00653-2","volume":"12","author":"J Li","year":"2024","unstructured":"Li J, Jia Z, Dong L, Cao H, Huang Y, Xu H, et al. DNA damage response in breast cancer and its significant role in guiding novel precise therapies. Biomark Res. 2024;12(1):111.","journal-title":"Biomark Res"},{"issue":"25","key":"908_CR57","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405.","journal-title":"N Engl J Med"},{"issue":"12","key":"908_CR58","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250\u201368.","journal-title":"Ann Oncol"},{"issue":"10","key":"908_CR59","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Di\u00e9ras","year":"2020","unstructured":"Di\u00e9ras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncol. 2020;21(10):1269\u201382.","journal-title":"The Lancet Oncol"},{"issue":"9","key":"908_CR60","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. The Lancet Oncol. 2020;21(9):1155\u201364.","journal-title":"The Lancet Oncol"},{"issue":"1","key":"908_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","volume":"30","author":"Y Drew","year":"2024","unstructured":"Drew Y, Kim JW, Penson RT, O\u2019Malley DM, Parkinson C, Roxburgh P, et al. Olaparib plus durvalumab, with or without Bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-Cohort study. Clin Cancer Res. 2024;30(1):50\u201362.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"908_CR62","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijrobp.2020.09.032","volume":"109","author":"P Loap","year":"2021","unstructured":"Loap P, Loirat D, Berger F, Ricci F, Vincent-Salomon A, Ezzili C, et al. Combination of olaparib and Radiation therapy for triple negative breast cancer: preliminary results of the RADIOPARP phase 1 trial. Int J Radiat Oncol Biol Phys. 2021;109(2):436\u201340.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"908_CR63","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","volume":"8","author":"P Loap","year":"2022","unstructured":"Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, et al. Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and Radiation therapy for triple-negative breast cancer trial. JAMA Oncol. 2022;8(12):1802\u201308.","journal-title":"JAMA Oncol"},{"issue":"4","key":"908_CR64","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTness): a randomised, phase 3 trial. The Lancet Oncol. 2018;19(4):497\u2013509.","journal-title":"The Lancet Oncol"},{"issue":"8014","key":"908_CR65","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","volume":"629","author":"JE Abraham","year":"2024","unstructured":"Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, et al. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature. 2024;629(8014):1142\u201348.","journal-title":"Nature"},{"issue":"6","key":"908_CR66","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333.","journal-title":"N Engl J Med"},{"key":"908_CR67","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","volume":"184","author":"ME Robson","year":"2023","unstructured":"Robson ME, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023;184:39\u201347.","journal-title":"Eur J Cancer"},{"issue":"8","key":"908_CR68","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753\u201363.","journal-title":"N Engl J Med"},{"issue":"11","key":"908_CR69","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gon\u00e7alves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526\u201335.","journal-title":"Ann Oncol"},{"issue":"10","key":"908_CR70","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/oncolo\/oyad139","volume":"28","author":"JK Litton","year":"2023","unstructured":"Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, et al. Neoadjuvant talazoparib in patients with germline BRCA1\/2 mutation-positive, early-stage triple-negative breast cancer: results of a phase II study. Oncologist. 2023;28(10):845\u201355.","journal-title":"Oncologist"},{"issue":"41","key":"908_CR71","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","volume":"69","author":"DA Siegel","year":"2020","unstructured":"Siegel DA, O\u2019Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and Race\/Ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020;69(41):1473\u201380.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"908_CR72","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","volume":"24","author":"G Attard","year":"2023","unstructured":"Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. The Lancet Oncol. 2023;24(5):443\u201356.","journal-title":"The Lancet Oncol"},{"issue":"3","key":"908_CR73","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354\u201373.","journal-title":"Endocr Rev"},{"issue":"23","key":"908_CR74","doi-asserted-by":"publisher","first-page":"12628","DOI":"10.3390\/ijms222312628","volume":"22","author":"S Shah","year":"2021","unstructured":"Shah S, Rachmat R, Enyioma S, Ghose A, Revythis A, Boussios S. BRCA mutations in prostate cancer: assessment, implications and treatment considerations. Int J Mol Sci. 2021;22(23):12628.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"908_CR75","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443\u201353.","journal-title":"N Engl J Med"},{"issue":"24","key":"908_CR76","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"908_CR77","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"de Bono J","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"issue":"8","key":"908_CR78","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or Physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719\u201332.","journal-title":"N Engl J Med"},{"issue":"15","key":"908_CR79","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1200\/JCO.23.02182","volume":"42","author":"BL Heiss","year":"2024","unstructured":"Heiss BL, Chang E, Gao X, Truong T, Brave MH, Bloomquist E, et al. US Food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. J Clin Oncol. 2024;42(15):1851\u201360.","journal-title":"J Clin Oncol"},{"issue":"1","key":"908_CR80","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024;30(1):257\u201364.","journal-title":"Nat Med"},{"issue":"10398","key":"908_CR81","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291\u2013303.","journal-title":"Lancet"},{"issue":"10","key":"908_CR82","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. The Lancet Oncol. 2023;24(10):1094\u2013108.","journal-title":"The Lancet Oncol"},{"issue":"5","key":"908_CR83","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.23.01868","volume":"42","author":"J Fallah","year":"2024","unstructured":"Fallah J, Xu J, Weinstock C, Brave MH, Bloomquist E, Fiero MH, et al. FDA approval summary: olaparib in combination with abiraterone for treatment of patients with BRCA-Mutated metastatic castration-resistant prostate cancer. J Clin Oncol. 2024;42(5):605\u201313.","journal-title":"J Clin Oncol"},{"issue":"18","key":"908_CR84","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41(18):3339\u201351.","journal-title":"J Clin Oncol"},{"issue":"10","key":"908_CR85","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jamaoncol.2024.3074","volume":"10","author":"CH Marshall","year":"2024","unstructured":"Marshall CH, Teply BA, Lu J, Oliveira L, Wang H, Mao SS, et al. Olaparib without androgen deprivation for high-risk biochemically recurrent prostate cancer following prostatectomy: a nonrandomized controlled trial. JAMA Oncol. 2024;10(10):1400\u201308.","journal-title":"JAMA Oncol"},{"issue":"9","key":"908_CR86","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851\u201362.","journal-title":"JAMA"},{"issue":"4","key":"908_CR87","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-Mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med"},{"issue":"34","key":"908_CR88","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-Mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40(34):3929\u201339.","journal-title":"J Clin Oncol"},{"issue":"8","key":"908_CR89","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","volume":"23","author":"KA Reiss","year":"2022","unstructured":"Reiss KA, Mick R, Teitelbaum U, O\u2019Hara M, Schneider C, Massa R, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. The Lancet Oncol. 2022;23(8):1009\u201320.","journal-title":"The Lancet Oncol"},{"issue":"1","key":"908_CR90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2022.09.025","volume":"83","author":"F Vignani","year":"2023","unstructured":"Vignani F, Tambaro R, De Giorgi U, Giannatempo P, Bimbatti D, Carella C, et al. Addition of niraparib to best supportive care as maintenance treatment in patients with advanced urothelial carcinoma whose disease did not progress after first-line platinum-based chemotherapy: the meet-URO12 randomized phase 2 trial. Eur Urol. 2023;83(1):82\u201389.","journal-title":"Eur Urol"},{"issue":"10","key":"908_CR91","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/annonc\/mdv308","volume":"26","author":"MR Middleton","year":"2015","unstructured":"Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, et al. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Ann Oncol. 2015;26(10):2173\u201379.","journal-title":"Ann Oncol"},{"issue":"11","key":"908_CR92","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1002\/cncr.31309","volume":"124","author":"MJ Pishvaian","year":"2018","unstructured":"Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, et al. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. 2018;124(11):2337\u201346.","journal-title":"Cancer"},{"issue":"8","key":"908_CR93","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jtho.2021.04.001","volume":"16","author":"X Ai","year":"2021","unstructured":"Ai X, Pan Y, Shi J, Yang N, Liu C, Zhou J, et al. Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: a randomized, double-blind, phase 3 study. J Thorac Oncol. 2021;16(8):1403\u201314.","journal-title":"J Thorac Oncol"},{"issue":"23","key":"908_CR94","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","volume":"36","author":"MC Pietanza","year":"2018","unstructured":"Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-Cell lung cancer. J Clin Oncol. 2018;36(23):2386\u201394.","journal-title":"J Clin Oncol"},{"key":"908_CR95","doi-asserted-by":"publisher","first-page":"107216","DOI":"10.1016\/j.lungcan.2023.107216","volume":"180","author":"MG Krebs","year":"2023","unstructured":"Krebs MG, Delord JP, Jeffry Evans TR, De Jonge M, Kim SW, Meurer M, et al. Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): an open-label, multicenter, phase 1\/2, basket study. Lung Cancer. 2023;180:107216.","journal-title":"Lung Cancer"},{"issue":"32","key":"908_CR96","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1200\/JCO.20.03318","volume":"39","author":"SS Ramalingam","year":"2021","unstructured":"Ramalingam SS, Novello S, Guclu SZ, Bentsion D, Zvirbule Z, Szilasi M, et al. Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced Squamous Cell lung cancer: a randomized, Multicenter phase III study. J Clin Oncol. 2021;39(32):3633\u201344.","journal-title":"J Clin Oncol"},{"issue":"3","key":"908_CR97","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cllc.2022.01.005","volume":"23","author":"R Govindan","year":"2022","unstructured":"Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, et al. Veliparib plus carboplatin and paclitaxel versus Investigator\u2019s choice of standard chemotherapy in patients with advanced non-squamous non-small cell lung cancer. Clin Lung Cancer. 2022;23(3):214\u201325.","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"908_CR98","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1158\/1078-0432.CCR-15-3069","volume":"23","author":"SS Ramalingam","year":"2017","unstructured":"Ramalingam SS, Blais N, Mazieres J, Reck M, Jones CM, Juhasz E, et al. Randomized, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for Advanced\/Metastatic non-small Cell lung cancer. Clin Cancer Res. 2017;23(8):1937\u201344.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"908_CR99","doi-asserted-by":"publisher","first-page":"189221","DOI":"10.1016\/j.bbcan.2024.189221","volume":"1879","author":"R Bi","year":"2024","unstructured":"Bi R, Chen L, Huang M, Qiao Z, Li Z, Fan G, et al. Emerging strategies to overcome PARP inhibitors\u2019 resistance in ovarian cancer. Biochim Biophys Acta Rev Cancer. 2024;1879(6):189221.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"16","key":"908_CR100","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","volume":"26","author":"S Lheureux","year":"2020","unstructured":"Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, et al. EVOLVE: a Multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin Cancer Res. 2020;26(16):4206\u201315.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"908_CR101","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, et al. Circulating Cell-free DNA to Guide prostate cancer treatment with PARP inhibition. Cancer Discov. 2017;7(9):1006\u201317.","journal-title":"Cancer Discov"},{"issue":"14","key":"908_CR102","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-22-3715","volume":"29","author":"YN Kim","year":"2023","unstructured":"Kim YN, Shim Y, Seo J, Choi Z, Lee YJ, Shin S, et al. Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-Mutated ovarian cancer. Clin Cancer Res. 2023;29(14):2725\u201334.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"908_CR103","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, et al. BRCA reversion mutations in Circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9(2):210\u201319.","journal-title":"Cancer Discov"},{"key":"908_CR104","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.11.012","volume":"125","author":"M Rusan","year":"2020","unstructured":"Rusan M, Andersen RF, Jakobsen A, Steffensen KD. Circulating HOXA9-methylated tumour DNA: a novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. Eur J Cancer. 2020;125:121\u201329.","journal-title":"Eur J Cancer"},{"issue":"10","key":"908_CR105","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020;19(10):711\u201336.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"908_CR106","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.trecan.2024.06.008","volume":"10","author":"D Dibitetto","year":"2024","unstructured":"Dibitetto D, Widmer CA, Rottenberg S. Parpi, BRCA, and gaps: controversies and future research. Trends Cancer. 2024;10(9):857\u201369.","journal-title":"Trends Cancer"},{"key":"908_CR107","doi-asserted-by":"crossref","unstructured":"Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015;7(4):a016600.","DOI":"10.1101\/cshperspect.a016600"},{"key":"908_CR108","doi-asserted-by":"crossref","unstructured":"Langelier MF, Lin X, Zha S, Pascal JM. Clinical PARP inhibitors allosterically induce PARP2 retention on DNA. Sci Adv. 2023;9(12):eadf 7175.","DOI":"10.1126\/sciadv.adf7175"},{"issue":"21","key":"908_CR109","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588\u201399.","journal-title":"Cancer Res"},{"issue":"3","key":"908_CR110","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1124\/jpet.113.210146","volume":"349","author":"J Murai","year":"2014","unstructured":"Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, et al. Rationale for Poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther. 2014;349(3):408\u201316.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"908_CR111","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","volume":"13","author":"TA Hopkins","year":"2015","unstructured":"Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res. 2015;13(11):1465\u201377.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"908_CR112","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10637-019-00867-4","volume":"38","author":"S Boussios","year":"2020","unstructured":"Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs. 2020;38(1):181\u201393.","journal-title":"Invest New Drugs"},{"issue":"1","key":"908_CR113","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","volume":"9","author":"SJ Pettitt","year":"2018","unstructured":"Pettitt SJ, Krastev DB, Brandsma I, Dr\u00e9an A, Song F, Aleksandrov R, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun. 2018;9(1):1849.","journal-title":"Nat Commun"},{"issue":"8007","key":"908_CR114","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","volume":"628","author":"M Petropoulos","year":"2024","unstructured":"Petropoulos M, Karamichali A, Rossetti GG, Freudenmann A, Iacovino LG, Dionellis VS, et al. Transcription-replication conflicts underlie sensitivity to PARP inhibitors. Nature. 2024;628(8007):433\u201341.","journal-title":"Nature"},{"issue":"5","key":"908_CR115","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1093\/nar\/gkad066","volume":"51","author":"N Laspata","year":"2023","unstructured":"Laspata N, Kaur P, Mersaoui Sofiane Y, Muoio D, Liu Zhiyan S, Bannister MH, et al. PARP1 associates with R-loops to promote their resolution and genome stability. Nucleic Acids Res. 2023;51(5):2215\u201337.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"908_CR116","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5(4):387\u201393.","journal-title":"Mol Oncol"},{"issue":"22","key":"908_CR117","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1016\/j.molcel.2021.09.005","volume":"81","author":"M Paes Dias","year":"2021","unstructured":"Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, et al. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1\/53BP1 double-deficient cells by exposing ssDNA gaps. Mol Cell. 2021;81(22):4692\u2013708.","journal-title":"Mol Cell"},{"issue":"15","key":"908_CR118","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1016\/j.molcel.2021.06.011","volume":"81","author":"K Cong","year":"2021","unstructured":"Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell. 2021;81(15):3128\u201344.","journal-title":"Mol Cell"},{"issue":"4","key":"908_CR119","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41594-022-00747-1","volume":"29","author":"A Vaitsiankova","year":"2022","unstructured":"Vaitsiankova A, Burdova K, Sobol M, Gautam A, Benada O, Hanzlikova H, et al. PARP inhibition impedes the maturation of nascent DNA strands during DNA replication. Nat Struct Mol Biol. 2022;29(4):329\u201338.","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"908_CR120","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/0008-5472.CAN-20-1602","volume":"81","author":"NJ Panzarino","year":"2021","unstructured":"Panzarino NJ, Krais JJ, Cong K, Peng M, Mosqueda M, Nayak SU, et al. Replication gaps underlie BRCA deficiency and therapy response. Cancer Res. 2021;81(5):1388\u201397.","journal-title":"Cancer Res"},{"issue":"7538","key":"908_CR121","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature14184","volume":"518","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, et al. Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair. Nature. 2015;518(7538):258\u201362.","journal-title":"Nature"},{"issue":"22","key":"908_CR122","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1016\/j.molcel.2022.09.013","volume":"82","author":"A Mann","year":"2022","unstructured":"Mann A, Ramirez-Otero MA, De Antoni A, Hanthi YW, Sannino V, Baldi G, et al. POL\u03b8 prevents MRE11-NBS1-CtIP-dependent fork breakage in the absence of BRCA2\/RAD51 by filling lagging-strand gaps. Mol Cell. 2022;82(22):4218\u201331.","journal-title":"Mol Cell"},{"issue":"24","key":"908_CR123","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1016\/j.molcel.2022.11.008","volume":"82","author":"O Belan","year":"2022","unstructured":"Belan O, Sebald M, Adamowicz M, Anand R, Vancevska A, Neves J, et al. POLQ seals post-replicative ssDNA gaps to maintain genome stability in BRCA-deficient cancer cells. Mol Cell. 2022;82(24):4664\u201380.","journal-title":"Mol Cell"},{"issue":"9","key":"908_CR124","doi-asserted-by":"publisher","first-page":"111716","DOI":"10.1016\/j.celrep.2022.111716","volume":"41","author":"A Schrempf","year":"2022","unstructured":"Schrempf A, Bernardo S, Arasa Verge EA, Ramirez Otero MA, Wilson J, Kirchhofer D, et al. POL\u03b8 processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells. Cell Rep. 2022;41(9):111716.","journal-title":"Cell Rep"},{"issue":"16","key":"908_CR125","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","volume":"66","author":"N McCabe","year":"2006","unstructured":"McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109\u201315.","journal-title":"Cancer Res"},{"issue":"23","key":"908_CR126","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-23-3785","volume":"30","author":"J Chou","year":"2024","unstructured":"Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, et al. Synthetic lethal targeting of CDK12-deficient prostate cancer with PARP inhibitors. Clin Cancer Res. 2024;30(23):5445\u201358.","journal-title":"Clin Cancer Res"},{"issue":"6\u20137","key":"908_CR127","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/emmm.200900041","volume":"1","author":"AM Mendes-Pereira","year":"2009","unstructured":"Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1(6\u20137):315\u201322.","journal-title":"EMBO Mol Med"},{"key":"908_CR128","doi-asserted-by":"crossref","unstructured":"Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, et al. 2-hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375):eaal 2463.","DOI":"10.1126\/scitranslmed.aal2463"},{"issue":"5","key":"908_CR129","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1158\/0008-5472.CAN-21-1843","volume":"82","author":"KM Lappin","year":"2022","unstructured":"Lappin KM, Barros EM, Jhujh SS, Irwin GW, McMillan H, Liberante FG, et al. Cancer-associated SF3B1 mutations confer a BRCA-Like cellular phenotype and synthetic lethality to PARP inhibitors. Cancer Res. 2022;82(5):819\u201330.","journal-title":"Cancer Res"},{"issue":"11","key":"908_CR130","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1182\/blood.2025028560","volume":"146","author":"BB Zeisig","year":"2025","unstructured":"Zeisig BB, Tsai CT, Virely C, Fung TK, Akin AT, Troadec E, et al. Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer. Blood. 2025;146(11):1314\u201330.","journal-title":"Blood"},{"issue":"6","key":"908_CR131","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ccell.2018.05.008","volume":"33","author":"E Gogola","year":"2018","unstructured":"Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, et al. Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality. Cancer Cell. 2018;33(6):1078\u201393.","journal-title":"Cancer Cell"},{"issue":"12","key":"908_CR132","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.molcel.2021.04.028","volume":"81","author":"E Prokhorova","year":"2021","unstructured":"Prokhorova E, Agnew T, Wondisford AR, Tellier M, Kaminski N, Beijer D, et al. Unrestrained poly-ADP-ribosylation provides insights into chromatin regulation and human disease. Mol Cell. 2021;81(12):2640\u201355.","journal-title":"Mol Cell"},{"issue":"4","key":"908_CR133","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s11010-020-04015-y","volume":"476","author":"B Wen","year":"2021","unstructured":"Wen B, Wei YT, Zhao K. The role of high mobility group protein B3 (HMGB3) in tumor proliferation and drug resistance. Mol Cell Biochem. 2021;476(4):1729\u201339.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"908_CR134","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","volume":"32","author":"L Tobalina","year":"2021","unstructured":"Tobalina L, Armenia J, Irving E, O\u2019Connor MJ, Forment JV. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann Oncol. 2021;32(1):103\u201312.","journal-title":"Ann Oncol"},{"issue":"1","key":"908_CR135","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12943-024-02048-1","volume":"23","author":"K Nesic","year":"2024","unstructured":"Nesic K, Krais JJ, Wang Y, Vandenberg CJ, Patel P, Cai KQ, et al. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. Mol Cancer. 2024;23(1):158.","journal-title":"Mol Cancer"},{"issue":"1","key":"908_CR136","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9(1):3970.","journal-title":"Nat Commun"},{"key":"908_CR137","doi-asserted-by":"crossref","unstructured":"Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, et al. Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. J Natl Cancer Inst. 2016;108(11):djw148.","DOI":"10.1093\/jnci\/djw148"},{"issue":"4","key":"908_CR138","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","volume":"35","author":"E Harvey-Jones","year":"2024","unstructured":"Harvey-Jones E, Raghunandan M, Robbez-Masson L, Magraner-Pardo L, Alaguthurai T, Yablonovitch A, et al. Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Ann Oncol. 2024;35(4):364\u201380.","journal-title":"Ann Oncol"},{"issue":"2","key":"908_CR139","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/nar\/gkx1208","volume":"46","author":"X Guo","year":"2018","unstructured":"Guo X, Bai Y, Zhao M, Zhou M, Shen Q, Yun CH, et al. Acetylation of 53BP1 dictates the DNA double strand break repair pathway. Nucleic Acids Res. 2018;46(2):689\u2013703.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"908_CR140","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/j.celrep.2018.04.046","volume":"23","author":"M Barazas","year":"2018","unstructured":"Barazas M, Annunziato S, Pettitt SJ, de Krijger I, Ghezraoui H, Roobol SJ, et al. The CST complex mediates end protection at double-strand breaks and promotes PARP inhibitor sensitivity in BRCA1-deficient cells. Cell Rep. 2018;23(7):2107\u201318.","journal-title":"Cell Rep"},{"issue":"2","key":"908_CR141","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2020.05.040","volume":"182","author":"M Olivieri","year":"2020","unstructured":"Olivieri M, Cho T, \u00c1lvarez-Quil\u00f3n A, Li K, Schellenberg MJ, Zimmermann M, et al. A genetic map of the response to DNA damage in human cells. Cell. 2020;182(2):481\u201396.","journal-title":"Cell"},{"issue":"8","key":"908_CR142","doi-asserted-by":"publisher","first-page":"108068","DOI":"10.1016\/j.celrep.2020.108068","volume":"32","author":"P Francica","year":"2020","unstructured":"Francica P, Mutlu M, Blomen VA, Oliveira C, Nowicka Z, Trenner A, et al. Functional radiogenetic profiling implicates ERCC6L2 in non-homologous end joining. Cell Rep. 2020;32(8):108068.","journal-title":"Cell Rep"},{"issue":"7732","key":"908_CR143","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41586-018-0670-5","volume":"563","author":"YJ He","year":"2018","unstructured":"He YJ, Meghani K, Caron MC, Yang C, Ronato DA, Bian J, et al. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature. 2018;563(7732):522\u201326.","journal-title":"Nature"},{"issue":"1","key":"908_CR144","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s10020-025-01066-z","volume":"31","author":"MA Kim","year":"2025","unstructured":"Kim MA, Kim B, Jeon J, Lee J, Jang H, Baek M, et al. Tousled-like kinase loss confers PARP inhibitor resistance in BRCA1-mutated cancers by impeding non-homologous end joining repair. Mol Med. 2025;31(1):18.","journal-title":"Mol Med"},{"issue":"1","key":"908_CR145","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-019-0442-y","volume":"22","author":"CS Clairmont","year":"2020","unstructured":"Clairmont CS, Sarangi P, Ponnienselvan K, Galli LD, Csete I, Moreau L, et al. TRIP13 regulates DNA repair pathway choice through REV7 conformational change. Nat Cell Biol. 2020;22(1):87\u201396.","journal-title":"Nat Cell Biol"},{"issue":"7644","key":"908_CR146","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nature21358","volume":"543","author":"P Dran\u00e9","year":"2017","unstructured":"Dran\u00e9 P, Brault ME, Cui G, Meghani K, Chaubey S, Detappe A, et al. TIRR regulates 53BP1 by masking its histone methyl-lysine binding function. Nature. 2017;543(7644):211\u201316.","journal-title":"Nature"},{"key":"908_CR147","doi-asserted-by":"publisher","first-page":"101085","DOI":"10.1016\/j.drup.2024.101085","volume":"74","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Tu X, Hou X, Yu J, Zhao F, Huang J, et al. Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy. Drug Resist Updat. 2024;74:101085.","journal-title":"Drug Resist Updat"},{"issue":"3","key":"908_CR148","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","volume":"14","author":"YE Choi","year":"2016","unstructured":"Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, et al. Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant ovarian cancer. Cell Rep. 2016;14(3):429\u201339.","journal-title":"Cell Rep"},{"issue":"1","key":"908_CR149","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41523-023-00540-3","volume":"9","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu Z, Gui L, Yun W, Mao C, Deng R, et al. Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer. NPJ Breast Cancer. 2023;9(1):34.","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"908_CR150","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.molcel.2015.12.013","volume":"61","author":"J Tk\u00e1\u010d","year":"2016","unstructured":"Tk\u00e1\u010d J, Xu G, Adhikary H, Young JTF, Gallo D, Escribano-D\u00edaz C, et al. HELB is a feedback inhibitor of DNA end resection. Mol Cell. 2016;61(3):405\u201318.","journal-title":"Mol Cell"},{"key":"908_CR151","doi-asserted-by":"crossref","unstructured":"Zhou Q, Tu X, Hou X, Yu J, Zhao F, Huang J, et al. Syk-dependent alternative homologous recombination activation promotes cancer resistance to DNA targeted therapy. ResearchSq. 2023.","DOI":"10.21203\/rs.3.rs-2922520\/v1"},{"issue":"8060","key":"908_CR152","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41586-025-08749-x","volume":"640","author":"S Lahiri","year":"2025","unstructured":"Lahiri S, Hamilton G, Moore G, Goehring L, Huang TT, Jensen RB, et al. BRCA2 prevents PARPi-mediated PARP1 retention to protect RAD51 filaments. Nature. 2025;640(8060):1103\u201311.","journal-title":"Nature"},{"key":"908_CR153","doi-asserted-by":"crossref","unstructured":"Wu Y, Chen S, Shao Y, Su Y, Li Q, Wu J, et al. KLF5 promotes tumor progression and Parp inhibitor resistance in ovarian cancer. Adv Sci (Weinh). 2023;10(31):e2304638.","DOI":"10.1002\/advs.202304638"},{"key":"908_CR154","doi-asserted-by":"publisher","first-page":"217505","DOI":"10.1016\/j.canlet.2025.217505","volume":"613","author":"H Li","year":"2025","unstructured":"Li H, Chatla S, Liu X, Tian Z, Vekariya U, Wang P, et al. ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Lett. 2025;613:217505.","journal-title":"Cancer Lett"},{"issue":"1","key":"908_CR155","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","volume":"14","author":"T Tsujino","year":"2023","unstructured":"Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, et al. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun. 2023;14(1):252.","journal-title":"Nat Commun"},{"issue":"17","key":"908_CR156","doi-asserted-by":"publisher","first-page":"8898","DOI":"10.1093\/nar\/gky657","volume":"46","author":"KE Clements","year":"2018","unstructured":"Clements KE, Thakar T, Nicolae CM, Liang X, Wang HG, Moldovan GL. Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells. Nucleic Acids Res. 2018;46(17):8898\u2013907.","journal-title":"Nucleic Acids Res"},{"key":"908_CR157","doi-asserted-by":"crossref","unstructured":"Deng Q, Qiang J, Liu C, Ding J, Tu J, He X, et al. SOSTDC1 nuclear translocation facilitates BTIC maintenance and CHD1-mediated HR repair to promote tumor progression and olaparib resistance in TNBC. Adv Sci (Weinh). 2024;11(29):e2306860.","DOI":"10.1002\/advs.202306860"},{"issue":"5721","key":"908_CR158","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1126\/science.1108297","volume":"308","author":"JH Lee","year":"2005","unstructured":"Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science. 2005;308(5721):551\u201354.","journal-title":"Science"},{"issue":"22","key":"908_CR159","doi-asserted-by":"publisher","first-page":"13881","DOI":"10.1093\/nar\/gkae1099","volume":"52","author":"Y Xu","year":"2024","unstructured":"Xu Y, Li C, Yin H, Nowsheen S, Xu X, Kang W, et al. STK39-mediated amplification of \u03b3-H2A.X promotes homologous recombination and contributes to PARP inhibitor resistance. Nucleic Acids Res. 2024;52(22):13881\u201395.","journal-title":"Nucleic Acids Res"},{"issue":"7612","key":"908_CR160","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535(7612):382\u201387.","journal-title":"Nature"},{"issue":"7612","key":"908_CR161","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, J-E L, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535(7612):382\u201387.","journal-title":"Nature"},{"issue":"12","key":"908_CR162","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41589-024-01611-7","volume":"20","author":"T Tian","year":"2024","unstructured":"Tian T, Chen J, Zhao H, Li Y, Xia F, Huang J, et al. UFL1 triggers replication fork degradation by MRE11 in BRCA1\/2-deficient cells. Nat Chem Biol. 2024;20(12):1650\u201361.","journal-title":"Nat Chem Biol"},{"issue":"11","key":"908_CR163","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/ncb3626","volume":"19","author":"B Rondinelli","year":"2017","unstructured":"Rondinelli B, Gogola E, Y\u00fccel H, Duarte AA, van de Ven M, van der Sluijs R, et al. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol. 2017;19(11):1371\u201378.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"908_CR164","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.molcel.2017.09.036","volume":"68","author":"A Taglialatela","year":"2017","unstructured":"Taglialatela A, Alvarez S, Leuzzi G, Sannino V, Ranjha L, Huang JW, et al. Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by Inactivation of SNF2-family fork remodelers. Mol Cell. 2017;68(2):414\u201330.","journal-title":"Mol Cell"},{"issue":"1","key":"908_CR165","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1038\/s41467-024-48715-1","volume":"15","author":"D Dibitetto","year":"2024","unstructured":"Dibitetto D, Liptay M, Vivalda F, Dogan H, Gogola E, Gonz\u00e1lez Fern\u00e1ndez M, et al. H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours. Nat Commun. 2024;15(1):4430.","journal-title":"Nat Commun"},{"issue":"3","key":"908_CR166","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12079-013-0203-9","volume":"7","author":"RC Baxter","year":"2013","unstructured":"Baxter RC. Insulin-like growth factor binding protein-3 (IGFBP-3): novel ligands mediate unexpected functions. J Cell Commun Signal. 2013;7(3):179\u201389.","journal-title":"J Cell Commun Signal"},{"issue":"2","key":"908_CR167","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1074\/jbc.M109.065615","volume":"285","author":"M Hammel","year":"2010","unstructured":"Hammel M, Yu Y, Mahaney BL, Cai B, Ye R, Phipps BM, et al. Ku and DNA-dependent protein kinase dynamic conformations and assembly regulate DNA binding and the initial non-homologous end joining complex. J Biol Chem. 2010;285(2):1414\u201323.","journal-title":"J Biol Chem"},{"issue":"2","key":"908_CR168","doi-asserted-by":"publisher","first-page":"108984","DOI":"10.1016\/j.isci.2024.108984","volume":"27","author":"AR Leslie","year":"2024","unstructured":"Leslie AR, Ning S, Armstrong CM, D\u2019Abronzo LS, Sharifi M, Schaaf ZA, et al. IGFBP3 promotes resistance to olaparib via modulating EGFR signaling in advanced prostate cancer. iScience. 2024;27(2):108984.","journal-title":"iScience"},{"issue":"1","key":"908_CR169","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13578-023-01117-0","volume":"13","author":"X Zhuang","year":"2023","unstructured":"Zhuang X, Xiao R, Fu Y, Yang B, Fan J, Lu F, et al. MRE11: p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC. Cell Biosci. 2023;13(1):178.","journal-title":"Cell Biosci"},{"issue":"8","key":"908_CR170","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41419-024-06984-0","volume":"15","author":"M Xiao","year":"2024","unstructured":"Xiao M, Yang J, Dong M, Mao X, Pan H, Lei Y, et al. NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy. Cell Death Dis. 2024;15(8):620.","journal-title":"Cell Death Dis"},{"issue":"44","key":"908_CR171","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA. 2008;105(44):17079\u201384.","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"1","key":"908_CR172","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","volume":"10","author":"EL Christie","year":"2019","unstructured":"Christie EL, Pattnaik S, Beach J, Copeland A, Rashoo N, Fereday S, et al. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nat Commun. 2019;10(1):1295.","journal-title":"Nat Commun"},{"issue":"22","key":"908_CR173","doi-asserted-by":"publisher","first-page":"14338","DOI":"10.3390\/ijms232214338","volume":"23","author":"Z Sabet","year":"2022","unstructured":"Sabet Z, Vagiannis D, Budagaga Y, Zhang Y, Novotn\u00e1 E, Hanke I, et al. Talazoparib does not interact with ABCB1 transporter or cytochrome P450s, but modulates multidrug resistance mediated by ABCC1 and ABCG2: an in vitro and ex vivo study. Int J Mol Sci. 2022;23(22):14338.","journal-title":"Int J Mol Sci"},{"key":"908_CR174","doi-asserted-by":"publisher","first-page":"101028","DOI":"10.1016\/j.drup.2023.101028","volume":"73","author":"QX Teng","year":"2024","unstructured":"Teng QX, Lei ZN, Wang JQ, Yang Y, Wu ZX, Acharekar ND, et al. Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor. Drug Resist Updat. 2024;73:101028.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"908_CR175","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12943-024-02025-8","volume":"23","author":"C Liu","year":"2024","unstructured":"Liu C, Li J, Xu F, Chen L, Ni M, Wu J, et al. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer. Mol Cancer. 2024;23(1):111.","journal-title":"Mol Cancer"},{"issue":"11","key":"908_CR176","doi-asserted-by":"publisher","first-page":"429","DOI":"10.62347\/XOPN6908","volume":"17","author":"H Guo","year":"2024","unstructured":"Guo H, Lu R, Yuan S, Xu F, Huang C, Li J, et al. Activation of cGAS confers PARP inhibitor resistance in ovarian cancer via the TBK1-IRF3 axis. Int J Clin Exp Pathol. 2024;17(11):429\u201338.","journal-title":"Int J Clin Exp Pathol"},{"issue":"15","key":"908_CR177","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1111\/jcmm.17802","volume":"27","author":"L Chi","year":"2023","unstructured":"Chi L, Huan L, Zhang C, Wang H, Lu J. Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL-6-STAT3 signalling. J Cell Mol Med. 2023;27(15):2150\u201364.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"908_CR178","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s12276-022-00809-w","volume":"54","author":"H Ma","year":"2022","unstructured":"Ma H, Qi G, Han F, Peng J, Yuan C, Kong B. PBK drives PARP inhibitor resistance through the TRIM37\/NF\u03baB axis in ovarian cancer. Exp Mol Med. 2022;54(7):999\u20131010.","journal-title":"Exp Mol Med"},{"issue":"3","key":"908_CR179","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s13402-023-00907-5","volume":"47","author":"Y Liu","year":"2024","unstructured":"Liu Y, Cao Y, Liu P, Zhai S, Liu Y, Tang X, et al. ATF3-induced activation of NF-\u03baB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma. Cell Oncol (Dordr). 2024;47(3):939\u201350.","journal-title":"Cell Oncol (Dordr)"},{"issue":"19","key":"908_CR180","doi-asserted-by":"publisher","first-page":"10427","DOI":"10.3390\/ijms251910427","volume":"25","author":"TB Petta","year":"2024","unstructured":"Petta TB, Carlson J. Exploring molecular drivers of PARPi resistance in BRCA1-deficient ovarian cancer: the role of LY6E and Immunomodulation. Int J Mol Sci. 2024;25(19):10427.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"908_CR181","doi-asserted-by":"publisher","first-page":"2432117","DOI":"10.1080\/15384047.2024.2432117","volume":"25","author":"M Gai","year":"2024","unstructured":"Gai M, Zhao L, Li H, Jin G, Li W, Wang F, et al. LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2\/STAT3 signalling pathway. Cancer Biol Ther. 2024;25(1):2432117.","journal-title":"Cancer Biol Ther"},{"key":"908_CR182","doi-asserted-by":"crossref","unstructured":"Mehibel M, Xu Y, Li CG, Moon EJ, Thakkar KN, Diep AN, et al. Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. J Clin Invest. 2021;131(11):e146256.","DOI":"10.1172\/JCI146256"},{"issue":"20","key":"908_CR183","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.1158\/0008-5472.CAN-10-2352","volume":"70","author":"N Chan","year":"2010","unstructured":"Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res. 2010;70(20):8045\u201354.","journal-title":"Cancer Res"},{"key":"908_CR184","doi-asserted-by":"publisher","first-page":"217192","DOI":"10.1016\/j.canlet.2024.217192","volume":"602","author":"H Wu","year":"2024","unstructured":"Wu H, Sun C, Cao W, Teng Q, Ma X, Schi\u00f6th HB, et al. Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer. Cancer Lett. 2024;602:217192.","journal-title":"Cancer Lett"},{"issue":"1\u20132","key":"908_CR185","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cell.2016.11.042","volume":"168","author":"Y Wei","year":"2017","unstructured":"Wei Y, Chiang WC, Sumpter R Jr, Mishra P, Levine B. Prohibitin 2 is an inner mitochondrial membrane mitophagy receptor. Cell. 2017;168(1\u20132):224\u201338.","journal-title":"Cell"},{"issue":"3","key":"908_CR186","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/15548627.2019.1628520","volume":"16","author":"C Yan","year":"2020","unstructured":"Yan C, Gong L, Chen L, Xu M, Abou-Hamdan H, Tang M, et al. PHB2 (prohibitin 2) promotes PINK1-PRKN\/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis. Autophagy. 2020;16(3):419\u201334.","journal-title":"Autophagy"},{"issue":"11","key":"908_CR187","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1158\/2767-9764.CRC-24-0339","volume":"4","author":"ZA Schaaf","year":"2024","unstructured":"Schaaf ZA, Ning S, Leslie AR, Sharifi M, Gao RY, Maine JP, et al. PINK1-mediated mitochondrial activity confers olaparib resistance in prostate cancer cells. Cancer Res Commun. 2024;4(11):2976\u201385.","journal-title":"Cancer Res Commun"},{"issue":"2","key":"908_CR188","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","volume":"23","author":"BH Lok","year":"2017","unstructured":"Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates Synergy with temozolomide in small Cell lung cancer. Clin Cancer Res. 2017;23(2):523\u201335.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"908_CR189","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","volume":"69","author":"J Murai","year":"2018","unstructured":"Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, et al. SLFN11 blocks stressed replication forks independently of ATR. Mol Cell. 2018;69(3):371\u201384.","journal-title":"Mol Cell"},{"issue":"1","key":"908_CR190","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1038\/s41467-021-24361-9","volume":"12","author":"E Prokhorova","year":"2021","unstructured":"Prokhorova E, Zobel F, Smith R, Zentout S, Gibbs-Seymour I, Sch\u00fctzenhofer K, et al. Serine-linked PARP1 auto-modification controls PARP inhibitor response. Nat Commun. 2021;12(1):4055.","journal-title":"Nat Commun"},{"key":"908_CR191","doi-asserted-by":"crossref","unstructured":"Zentout S, Imburchia V, Chapuis C, Duma L, Sch\u00fctzenhofer K, Prokhorova E, et al. Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions. Proc Natl Acad Sci USA. 2024;121(25):e2322689121.","DOI":"10.1073\/pnas.2322689121"},{"issue":"1","key":"908_CR192","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2011","unstructured":"Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12(1):68\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"7676","key":"908_CR193","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature24060","volume":"550","author":"W Zhao","year":"2017","unstructured":"Zhao W, Steinfeld JB, Liang F, Chen X, Maranon DG, Jian Ma C, et al. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature. 2017;550(7676):360\u201365.","journal-title":"Nature"},{"issue":"12","key":"908_CR194","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","volume":"42","author":"G Seed","year":"2024","unstructured":"Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, et al. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell. 2024;42(12):2113\u201323.","journal-title":"Cancer Cell"},{"issue":"7716","key":"908_CR195","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-018-0362-1","volume":"560","author":"H Ghezraoui","year":"2018","unstructured":"Ghezraoui H, Oliveira C, Becker JR, Bilham K, Moralli D, Anzilotti C, et al. 53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ. Nature. 2018;560(7716):122\u201327.","journal-title":"Nature"},{"issue":"2","key":"908_CR196","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","volume":"141","author":"SF Bunting","year":"2010","unstructured":"Bunting SF, Call\u00e9n E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141(2):243\u201354.","journal-title":"Cell"},{"key":"908_CR197","doi-asserted-by":"crossref","unstructured":"Bell JC, Dombrowski CC, Plank JL, Jensen RB, Kowalczykowski SC. BRCA2 chaperones RAD51 to single molecules of RPA-coated ssDNA. Proc Natl Acad Sci USA. 2023;120(14):e2221971120.","DOI":"10.1073\/pnas.2221971120"},{"issue":"10","key":"908_CR198","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrm2008","volume":"7","author":"P Sung","year":"2006","unstructured":"Sung P, Klein H. Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat Rev Mol Cell Biol. 2006;7(10):739\u201350.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"908_CR199","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.molcel.2023.12.026","volume":"84","author":"D Dibitetto","year":"2024","unstructured":"Dibitetto D, Rottenberg S. DNA repair, gap suppression, or fork protection: BRCA2 needs a break! Mol Cell. 2024;84(3):409\u201310.","journal-title":"Mol Cell"},{"issue":"1","key":"908_CR200","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ccr.2012.05.015","volume":"22","author":"K Schlacher","year":"2012","unstructured":"Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1\/2. Cancer Cell. 2012;22(1):106\u201316.","journal-title":"Cancer Cell"},{"key":"908_CR201","doi-asserted-by":"publisher","first-page":"15981","DOI":"10.1038\/ncomms15981","volume":"8","author":"PM Schoonen","year":"2017","unstructured":"Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, et al. Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. Nat Commun. 2017;8:15981.","journal-title":"Nat Commun"},{"issue":"11","key":"908_CR202","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1016\/j.celrep.2016.05.031","volume":"15","author":"Z Kais","year":"2016","unstructured":"Kais Z, Rondinelli B, Holmes A, O\u2019Leary C, Kozono D, D\u2019Andrea AD, et al. FANCD2 maintains fork stability in BRCA1\/2-deficient tumors and promotes alternative end-joining DNA repair. Cell Rep. 2016;15(11):2488\u201399.","journal-title":"Cell Rep"},{"issue":"8","key":"908_CR203","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nsmb.3252","volume":"23","author":"J Michl","year":"2016","unstructured":"Michl J, Zimmer J, Buffa FM, McDermott U, Tarsounas M. FANCD2 limits replication stress and genome instability in cells lacking BRCA2. Nat Struct Mol Biol. 2016;23(8):755\u201357.","journal-title":"Nat Struct Mol Biol"},{"issue":"7","key":"908_CR204","doi-asserted-by":"publisher","first-page":"114464","DOI":"10.1016\/j.celrep.2024.114464","volume":"43","author":"Z Liu","year":"2024","unstructured":"Liu Z, Jiang H, Lee SY, Kong N, Chan YW. FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition. Cell Rep. 2024;43(7):114464.","journal-title":"Cell Rep"},{"issue":"41","key":"908_CR205","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/s41388-024-03105-1","volume":"43","author":"H Ikeuchi","year":"2024","unstructured":"Ikeuchi H, Matsuno Y, Kusumoto-Matsuo R, Kojima S, Ueno T, Ikegami M, et al. GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway. Oncogene. 2024;43(41):3037\u201348.","journal-title":"Oncogene"},{"issue":"1","key":"908_CR206","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1631\/jzus.B2000289","volume":"22","author":"S Qiu","year":"2021","unstructured":"Qiu S, Huang J. MRN complex is an essential effector of DNA damage repair. J Zhejiang Univ Sci B. 2021;22(1):31\u201337.","journal-title":"J Zhejiang Univ Sci B"},{"key":"908_CR207","doi-asserted-by":"publisher","first-page":"216078","DOI":"10.1016\/j.canlet.2023.216078","volume":"557","author":"J Li","year":"2023","unstructured":"Li J, Song C, Gu J, Li C, Zang W, Shi L, et al. RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance. Cancer Lett. 2023;557:216078.","journal-title":"Cancer Lett"},{"issue":"4","key":"908_CR208","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/0008-5472.CAN-14-0839","volume":"75","author":"JE Jaspers","year":"2015","unstructured":"Jaspers JE, Sol W, Kersbergen A, Schlicker A, Guyader C, Xu G, et al. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance. Cancer Res. 2015;75(4):732\u201341.","journal-title":"Cancer Res"},{"issue":"4","key":"908_CR209","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/bjc.2016.203","volume":"115","author":"A Vaidyanathan","year":"2016","unstructured":"Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE, et al. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016;115(4):431\u201341.","journal-title":"Br J Cancer"},{"issue":"9","key":"908_CR210","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1007\/s00432-022-04503-2","volume":"149","author":"M Boeschen","year":"2023","unstructured":"Boeschen M, Le Duc D, Stiller M, von Laffert M, Sch\u00f6neberg T, Horn S. Interactive webtool for analyzing drug sensitivity and resistance associated with genetic signatures of cancer cell lines. J Cancer ResearchClin Oncol. 2023;149(9):5539\u201345.","journal-title":"J Cancer ResearchClin Oncol"},{"issue":"1","key":"908_CR211","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11095-014-1442-z","volume":"32","author":"S Durmus","year":"2015","unstructured":"Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res. 2015;32(1):37\u201346.","journal-title":"Pharm Res"},{"issue":"12","key":"908_CR212","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1158\/1535-7163.MCT-15-0553","volume":"14","author":"KE Parrish","year":"2015","unstructured":"Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, et al. Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous System. Mol Cancer Ther. 2015;14(12):2735\u201343.","journal-title":"Mol Cancer Ther"},{"issue":"6121","key":"908_CR213","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339(6121):786\u201391.","journal-title":"Science"},{"issue":"6121","key":"908_CR214","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1126\/science.1229963","volume":"339","author":"J Wu","year":"2013","unstructured":"Wu J, Sun L, Chen X, Du F, Shi H, Chen C, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339(6121):826\u201330.","journal-title":"Science"},{"key":"908_CR215","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-biochem-061516-044813","volume":"86","author":"K Kato","year":"2017","unstructured":"Kato K, Omura H, Ishitani R, Nureki O. Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA. Annu Rev Biochem. 2017;86:541\u201366.","journal-title":"Annu. Rev. Biochem"},{"issue":"11","key":"908_CR216","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","volume":"20","author":"M Motwani","year":"2019","unstructured":"Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet. 2019;20(11):657\u201374.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"908_CR217","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13578-023-01151-y","volume":"13","author":"MA Bustos","year":"2023","unstructured":"Bustos MA, Yokoe T, Shoji Y, Kobayashi Y, Mizuno S, Murakami T, et al. MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer. Cell Biosci. 2023;13(1):200.","journal-title":"Cell Biosci"},{"issue":"7","key":"908_CR218","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3390\/genes15070959","volume":"15","author":"S Choi","year":"2024","unstructured":"Choi S, Bae HG, Jo DG, Kim WY. The role of IRF9 upregulation in modulating sensitivity to olaparib and platinum-based chemotherapies in breast cancer. Genes (Basel). 2024;15(7):959.","journal-title":"Genes (Basel)"},{"key":"908_CR219","doi-asserted-by":"publisher","first-page":"101151","DOI":"10.1016\/j.drup.2024.101151","volume":"77","author":"Y Xue","year":"2024","unstructured":"Xue Y, Yin T, Yuan S, Wang L, Lin H, Jin T, et al. CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer. Drug Resist Updat. 2024;77:101151.","journal-title":"Drug Resist Updat"},{"issue":"7841","key":"908_CR220","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-020-3017-y","volume":"589","author":"N Yusufova","year":"2021","unstructured":"Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. 2021;589(7841):299\u2013305.","journal-title":"Nature"},{"issue":"1","key":"908_CR221","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41467-019-09232-8","volume":"10","author":"Y Peng","year":"2019","unstructured":"Peng Y, Liao Q, Tan W, Peng C, Hu Z, Chen Y, et al. The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors. Nat Commun. 2019;10(1):1224.","journal-title":"Nat Commun"},{"issue":"1","key":"908_CR222","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1038\/s41467-019-10993-5","volume":"10","author":"JF Ning","year":"2019","unstructured":"Ning JF, Stanciu M, Humphrey MR, Gorham J, Wakimoto H, Nishihara R, et al. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nat Commun. 2019;10(1):2910.","journal-title":"Nat Commun"},{"key":"908_CR223","doi-asserted-by":"publisher","first-page":"101928","DOI":"10.1016\/j.redox.2021.101928","volume":"42","author":"T Hong","year":"2021","unstructured":"Hong T, Lei G, Chen X, Li H, Zhang X, Wu N, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 2021;42:101928.","journal-title":"Redox Biol"},{"key":"908_CR224","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2021.10.006","volume":"81","author":"J Liu","year":"2022","unstructured":"Liu J, Erenpreisa J, Sikora E. Polyploid giant cancer cells: an emerging new field of cancer biology. Semin Cancer Biol. 2022;81:1\u20134.","journal-title":"Semin Cancer Biol"},{"key":"908_CR225","doi-asserted-by":"crossref","unstructured":"Zhang X, Yao J, Li X, Niu N, Liu Y, Hajek RA, et al. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci Adv. 2023;9(29):eadf 7195.","DOI":"10.1126\/sciadv.adf7195"},{"issue":"1","key":"908_CR226","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41392-023-01401-y","volume":"8","author":"C Zhang","year":"2023","unstructured":"Zhang C, Guo Q, Chen L, Wu Z, Yan XJ, Zou C, et al. A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors. Signal Transduct Target Ther. 2023;8(1):183.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"908_CR227","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19(1):107.","journal-title":"Mol Cancer"},{"issue":"15","key":"908_CR228","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"PC Fong","year":"2010","unstructured":"Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512\u201319.","journal-title":"J Clin Oncol"},{"issue":"9737","key":"908_CR229","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245\u201351.","journal-title":"Lancet"},{"issue":"6","key":"908_CR230","doi-asserted-by":"publisher","first-page":"100632","DOI":"10.1016\/j.esmoop.2022.100632","volume":"7","author":"S Gulia","year":"2022","unstructured":"Gulia S, Kannan S, Gupta S. Maintenance therapy with a poly (ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: updated individual patient data and trial-level meta-analysis. ESMO Open. 2022;7(6):100632.","journal-title":"ESMO Open"},{"issue":"1","key":"908_CR231","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. The Lancet Oncol. 2017;18(1):75\u201387.","journal-title":"The Lancet Oncol"},{"issue":"10","key":"908_CR232","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","volume":"20","author":"MR Mirza","year":"2019","unstructured":"Mirza MR, \u00c5vall Lundqvist E, Birrer MJ, DePont Christensen R, Nyvang G-B, Malander S, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial. The Lancet Oncol. 2019;20(10):1409\u201319.","journal-title":"The Lancet Oncol"},{"issue":"11","key":"908_CR233","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.19.02960","volume":"38","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(11):1222\u201345.","journal-title":"J Clin Oncol"},{"issue":"3","key":"908_CR234","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","volume":"33","author":"I Vergote","year":"2022","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Ray-Coquard I, Harter P, Colombo N, Pujol P, et al. European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022;33(3):276\u201387.","journal-title":"Ann Oncol"},{"issue":"12","key":"908_CR235","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","volume":"31","author":"RE Miller","year":"2020","unstructured":"Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606\u201322.","journal-title":"Ann Oncol"},{"issue":"1","key":"908_CR236","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2022.01.034","volume":"165","author":"A Vanderstichele","year":"2022","unstructured":"Vanderstichele A, Van Nieuwenhuysen E, Han S, Concin N, Van Gorp T, Berteloot P, et al. Randomized CLIO\/BGOG-ov10 trial of olaparib monotherapy versus physician\u2019s choice chemotherapy in relapsed ovarian cancer. Gynecol Oncol. 2022;165(1):14\u201322.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"908_CR237","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41416-018-0274-8","volume":"119","author":"DR Hodgson","year":"2018","unstructured":"Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Br J Cancer. 2018;119(11):1401\u201309.","journal-title":"Br J Cancer"},{"issue":"2","key":"908_CR238","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ygyno.2017.12.004","volume":"148","author":"SS Bernards","year":"2018","unstructured":"Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, et al. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. Gynecol Oncol. 2018;148(2):281\u201385.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"908_CR239","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.ejca.2014.05.001","volume":"50","author":"I Ruscito","year":"2014","unstructured":"Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - a study of the Tumour Bank Ovarian Cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). Eur J Cancer. 2014;50(12):2090\u201398.","journal-title":"Eur J Cancer"},{"key":"908_CR240","doi-asserted-by":"publisher","first-page":"115534","DOI":"10.1016\/j.ejca.2025.115534","volume":"225","author":"H Blons","year":"2025","unstructured":"Blons H, Abdelli J, Landman S, Taly V, Mulot C, Laurent-Puig P, et al. Predictive value of BRCA1\/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1\/ENGOT-ov25 phase 3 trial. Eur J Cancer. 2025;225:115534.","journal-title":"Eur J Cancer"},{"issue":"16","key":"908_CR241","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-22-3328","volume":"29","author":"F Blanc-Durand","year":"2023","unstructured":"Blanc-Durand F, Tang R, Pommier M, Nashvi M, Cotteret S, Genestie C, et al. Clinical Relevance of BRCA1 promoter methylation testing in patients with ovarian cancer. Clin Cancer Res. 2023;29(16):3124\u201329.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"908_CR242","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776\u201382.","journal-title":"Br J Cancer"},{"issue":"1","key":"908_CR243","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-025-00740-y","volume":"13","author":"A Witz","year":"2025","unstructured":"Witz A, Dardare J, Betz M, Michel C, Husson M, Gilson P, et al. Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics. Biomark Res. 2025;13(1):31.","journal-title":"Biomark Res"},{"issue":"12","key":"908_CR244","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1158\/2767-9764.CRC-24-0294","volume":"4","author":"MK Kjeldsen","year":"2024","unstructured":"Kjeldsen MK, J\u00f8rgensen M, Gr\u00f8nseth DSB, Sch\u00f8nemann-Lund M, Nyvang GB, Haslund CA, et al. Beyond HRD status: unraveling genetic variants impacting PARP inhibitor sensitivity in advanced ovarian cancer. Cancer Res Commun. 2024;4(12):3190\u2013200.","journal-title":"Cancer Res Commun"},{"issue":"3","key":"908_CR245","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/bcr3670","volume":"16","author":"JA Watkins","year":"2014","unstructured":"Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014;16(3):211.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"908_CR246","doi-asserted-by":"publisher","first-page":"105060","DOI":"10.1016\/j.esmoop.2025.105060","volume":"10","author":"L Beltrame","year":"2025","unstructured":"Beltrame L, Mannarino L, Sergi A, Velle A, Treilleux I, Pignata S, et al. HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib. ESMO Open. 2025;10(6):105060.","journal-title":"ESMO Open"},{"issue":"12","key":"908_CR247","doi-asserted-by":"publisher","first-page":"101344","DOI":"10.1016\/j.xcrm.2023.101344","volume":"4","author":"C Pozzorini","year":"2023","unstructured":"Pozzorini C, Andre G, Coletta T, Buisson A, Bieler J, Ferrer L, et al. Giinger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles. Cell Rep. Med. 2023;4(12):101344.","journal-title":"Cell Rep. Med"},{"key":"908_CR248","doi-asserted-by":"crossref","unstructured":"Liu R, Roberts E, Parsons HA, Stover EH, Choudhury AD, Rhoades J, et al. DirectHRD enables sensitive scar-based classification of homologous recombination deficiency. Nucleic Acids Res. 2025;53(8):gkaf313.","DOI":"10.1093\/nar\/gkaf313"},{"issue":"5","key":"908_CR249","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","volume":"51","author":"DC Gulhan","year":"2019","unstructured":"Gulhan DC, Lee JJ, Melloni GEM, Cort\u00e9s-Ciriano I, Park PJ. Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nat Genet. 2019;51(5):912\u201319.","journal-title":"Nat Genet"},{"issue":"1\u20132","key":"908_CR250","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1\u20132):373\u201386.","journal-title":"Cell"},{"issue":"4","key":"908_CR251","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. Hrdetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23(4):517\u201325.","journal-title":"Nat Med"},{"issue":"13","key":"908_CR252","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/0008-5472.CAN-25-2105","volume":"85","author":"J Lim","year":"2025","unstructured":"Lim J, Ju YS. Leveraging whole-exome sequencing and mutational signatures to detect homologous recombination deficiency in cancer. Cancer Res. 2025;85(13):2348\u201350.","journal-title":"Cancer Res"},{"key":"908_CR253","doi-asserted-by":"publisher","first-page":"1351778","DOI":"10.3389\/fonc.2024.1351778","volume":"14","author":"YN Kim","year":"2024","unstructured":"Kim YN, Kim K, Joung JG, Kim SW, Kim S, Lee JY, et al. RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer. Front Oncol. 2024;14:1351778.","journal-title":"Front Oncol"},{"issue":"5","key":"908_CR254","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","volume":"29","author":"C Cruz","year":"2018","unstructured":"Cruz C, Castroviejo-Bermejo M, Guti\u00e9rrez-Enr\u00edquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29(5):1203\u201310.","journal-title":"Ann Oncol"},{"issue":"16","key":"908_CR255","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1158\/1078-0432.CCR-22-3156","volume":"29","author":"S Pikkusaari","year":"2023","unstructured":"Pikkusaari S, Tumiati M, Virtanen A, Oikkonen J, Li Y, Perez-Villatoro F, et al. Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes. Clin Cancer Res. 2023;29(16):3110\u201323.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"908_CR256","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1158\/0008-5472.CAN-21-2409","volume":"82","author":"B Pellegrino","year":"2022","unstructured":"Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fern\u00e1ndez A, Viaplana C, et al. Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification. Cancer Res. 2022;82(8):1646\u201357.","journal-title":"Cancer Res"},{"key":"908_CR257","doi-asserted-by":"publisher","first-page":"1390116","DOI":"10.3389\/fphar.2024.1390116","volume":"15","author":"F Guffanti","year":"2024","unstructured":"Guffanti F, Mengoli I, Alvisi MF, Dellavedova G, Giavazzi R, Fruscio R, et al. BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models. Front Pharmacol. 2024;15:1390116.","journal-title":"Front Pharmacol"},{"key":"908_CR258","doi-asserted-by":"crossref","unstructured":"Schab A, Compadre A, Drexler R, Loeb M, Rodriguez K, Brill J, et al. Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer. J Clin Invest. 2025;135(13):e189511.","DOI":"10.1172\/JCI189511"},{"issue":"3","key":"908_CR259","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ygyno.2020.08.035","volume":"159","author":"K Fuh","year":"2020","unstructured":"Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, et al. Homologous recombination deficiency real-time clinical assays, ready or not? Gynecol Oncol. 2020;159(3):877\u201386.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"908_CR260","doi-asserted-by":"publisher","first-page":"100585","DOI":"10.1016\/j.esmoop.2022.100585","volume":"7","author":"ED Capoluongo","year":"2022","unstructured":"Capoluongo ED, Pellegrino B, Arenare L, Califano D, Scambia G, Beltrame L, et al. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A\/MaNGO-OV2 trial. ESMO Open. 2022;7(5):100585.","journal-title":"ESMO Open"},{"issue":"11","key":"908_CR261","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018;8(11):1404\u201321.","journal-title":"Cancer Discov"},{"key":"908_CR262","doi-asserted-by":"publisher","first-page":"106232","DOI":"10.1016\/j.phrs.2022.106232","volume":"179","author":"M Tao","year":"2022","unstructured":"Tao M, Sun F, Wang J, Wang Y, Zhu H, Chen M, et al. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer. Pharmacol Res. 2022;179:106232.","journal-title":"Pharmacol Res"},{"issue":"1","key":"908_CR263","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s13046-021-02139-7","volume":"40","author":"M Tao","year":"2021","unstructured":"Tao M, Wu X. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing. J Exp Clin Cancer Res. 2021;40(1):338.","journal-title":"J Exp Clin Cancer Res"},{"key":"908_CR264","doi-asserted-by":"publisher","first-page":"216180","DOI":"10.1016\/j.canlet.2023.216180","volume":"562","author":"R Yang","year":"2023","unstructured":"Yang R, Yu Y. Patient-derived organoids in translational oncology and drug screening. Cancer Lett. 2023;562:216180.","journal-title":"Cancer Lett"},{"issue":"2","key":"908_CR265","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/ijc.34947","volume":"155","author":"LM Fr\u00f6hlich","year":"2024","unstructured":"Fr\u00f6hlich LM, Villar-Miyar A, Heintze T, Sauer B, Schittek B. PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma. Int. J Cancer. 2024;155(2):203\u201310.","journal-title":"Int. J Cancer"},{"issue":"12","key":"908_CR266","doi-asserted-by":"publisher","first-page":"100872","DOI":"10.1016\/j.xcrm.2022.100872","volume":"3","author":"T Lazard","year":"2022","unstructured":"Lazard T, Bataillon G, Naylor P, Popova T, Bidard FC, Stoppa-Lyonnet D, et al. Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images. Cell Rep. Med. 2022;3(12):100872.","journal-title":"Cell Rep. Med"},{"key":"908_CR267","doi-asserted-by":"publisher","first-page":"102464","DOI":"10.1016\/j.media.2022.102464","volume":"79","author":"Y Schirris","year":"2022","unstructured":"Schirris Y, Gavves E, Nederlof I, Horlings HM, Teuwen J. DeepSMILE: contrastive self-supervised pre-training benefits MSI and HRD classification directly from H&E whole-slide images in colorectal and breast cancer. Med Image Anal. 2022;79:102464.","journal-title":"Med Image Anal"},{"issue":"12","key":"908_CR268","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.3390\/cancers12123687","volume":"12","author":"R Valieris","year":"2020","unstructured":"Valieris R, Amaro L, Os\u00f3rio C, Bueno AP, Rosales Mitrowsky RA, Carraro DM, et al. Deep learning predicts underlying features on pathology images with therapeutic Relevance for breast and gastric cancer. Cancers (Basel). 2020;12(12):3687.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"908_CR269","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s43018-020-0087-6","volume":"1","author":"JN Kather","year":"2020","unstructured":"Kather JN, Heij LR, Grabsch HI, Loeffler C, Echle A, Muti HS, et al. Pan-cancer image-based detection of clinically actionable genetic alterations. Nat Cancer. 2020;1(8):789\u201399.","journal-title":"Nat Cancer"},{"issue":"1","key":"908_CR270","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41467-024-45589-1","volume":"15","author":"OSM El Nahhas","year":"2024","unstructured":"El Nahhas OSM, Loeffler CML, Carrero ZI, van Treeck M, Kolbinger FR, Hewitt KJ, et al. Regression-based deep-learning predicts molecular biomarkers from pathology slides. Nat Commun. 2024;15(1):1253.","journal-title":"Nat Commun"},{"issue":"1","key":"908_CR271","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12915-024-02022-9","volume":"22","author":"CML Loeffler","year":"2024","unstructured":"Loeffler CML, El Nahhas OSM, Muti HS, Carrero ZI, Seibel T, van Treeck M, et al. Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types. BMC Biol. 2024;22(1):225.","journal-title":"BMC Biol"},{"issue":"1","key":"908_CR272","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41698-025-00950-5","volume":"9","author":"H Luan","year":"2025","unstructured":"Luan H, Hu T, Hu J, Liu W, Yang K, Pei Y, et al. Breast cancer homologous recombination deficiency prediction from pathological images with a sufficient and representative Transformer. NPJ Precis Oncol. 2025;9(1):160.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"908_CR273","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12967-025-06234-7","volume":"23","author":"K Zhang","year":"2025","unstructured":"Zhang K, Qiu Y, Feng S, Yin H, Liu Q, Zhu Y, et al. Development of model for identifying homologous recombination deficiency (HRD) status of ovarian cancer with deep learning on whole slide images. J Transl Med. 2025;23(1):267.","journal-title":"J Transl Med"},{"issue":"16","key":"908_CR274","doi-asserted-by":"publisher","first-page":"12978","DOI":"10.3390\/ijms241612978","volume":"24","author":"Rivero Belench\u00f3n","year":"2023","unstructured":"Rivero Belench\u00f3n, Congregado Ruiz CB, Saez C, Osman Garc\u00eda, Medina L\u00f3pez. Parp inhibitors and radiotherapy: a new combination for prostate cancer (systematic review). Int J Mol Sci. 2023;24(16):12978.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"908_CR275","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s44318-024-00043-2","volume":"43","author":"C Andronikou","year":"2024","unstructured":"Andronikou C, Burdova K, Dibitetto D, Lieftink C, Malzer E, Kuiken HJ, et al. PARG-deficient tumor cells have an increased dependence on EXO1\/FEN1-mediated DNA repair. Embo J. 2024;43(6):1015\u201342.","journal-title":"Embo J"},{"issue":"22","key":"908_CR276","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.3390\/cancers14225559","volume":"14","author":"HL Smith","year":"2022","unstructured":"Smith HL, Willmore E, Mukhopadhyay A, Drew Y, Curtin NJ. Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling. Cancers (Basel). 2022;14(22):5559.","journal-title":"Cancers (Basel)"},{"issue":"12_Supplement","key":"908_CR277","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1158\/1538-7445.AM2022-5338","volume":"82","author":"M Deng","year":"2022","unstructured":"Deng M, Qin K, Li Y, Jiang Y, Jin W, Shen Z. Abstract, 5338: pamiparib as a non-p-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells. Cancer Res. 2022;82(12_Supplement):5338.","journal-title":"Cancer Res"},{"issue":"1","key":"908_CR278","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","volume":"16","author":"A Herencia-Ropero","year":"2024","unstructured":"Herencia-Ropero A, Llop-Guevara A, Staniszewska AD, Dom\u00e8nech-Viv\u00f3 J, Garc\u00eda-Galea E, Moles-Fern\u00e1ndez A, et al. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models. Genome Med. 2024;16(1):107.","journal-title":"Genome Med"},{"key":"908_CR279","doi-asserted-by":"crossref","unstructured":"Yap TA, Im S-A, Schram AM, Sharp A, Balmana J, Baird RD, et al. Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations. Cancer Res. 2022;82(12_Supplement):CT007\u2013CT.","DOI":"10.1158\/1538-7445.AM2022-CT007"},{"issue":"9","key":"908_CR280","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1021\/acsmedchemlett.3c00308","volume":"14","author":"RB Kargbo","year":"2023","unstructured":"Kargbo RB. PARP7 inhibition: a promising pathway to advancements in cancer therapy. ACS Med Chem Lett. 2023;14(9):1141\u201343.","journal-title":"ACS Med Chem Lett"},{"key":"908_CR281","doi-asserted-by":"crossref","unstructured":"Wang LM, Wang P, Chen XM, Yang H, Song SS, Song Z, et al. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance. EMBO Mol Med. 2023;15(3):e16235.","DOI":"10.15252\/emmm.202216235"},{"issue":"17","key":"908_CR282","doi-asserted-by":"publisher","first-page":"12284","DOI":"10.1021\/acs.jmedchem.3c00821","volume":"66","author":"Y Sun","year":"2023","unstructured":"Sun Y, Yang H, Yuan J, Wang L, Song S, Chen R, et al. YCH1899, a highly effective phthalazin-1(2H)-one derivative that overcomes resistance to prior PARP inhibitors. J Med Chem. 2023;66(17):12284\u2013303.","journal-title":"J Med Chem"},{"issue":"6","key":"908_CR283","first-page":"1407","volume":"29","author":"L Zhu","year":"2024","unstructured":"Zhu L, Liu B, Jin F, Cao W, Xu G, Zhang X, et al. Discovery of novel 4-hydroxyquinazoline derivatives. Silico, vivo in vitro stud using primary PARPi-resistant cell lines mol. 2024;29(6):1407.","journal-title":"Silico, Vivo In Vitro Stud Using Primary PARPi-Resistant Cell Lines. Mol"},{"key":"908_CR284","doi-asserted-by":"crossref","unstructured":"Li P, Zhen Y, Kim C, Liu Z, Hao J, Deng H, et al. Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer. Sci Adv. 2023;9(43):eadg 7752.","DOI":"10.1126\/sciadv.adg7752"},{"issue":"1","key":"908_CR285","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","volume":"8","author":"M Asim","year":"2017","unstructured":"Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8(1):374.","journal-title":"Nat Commun"},{"issue":"12","key":"908_CR286","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-14-0173","volume":"12","author":"OS Chao","year":"2014","unstructured":"Chao OS, Goodman OB Jr. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP. Mol Cancer Res. 2014;12(12):1755\u201366.","journal-title":"Mol Cancer Res"},{"key":"908_CR287","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","volume":"17","author":"A Min","year":"2015","unstructured":"Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res. 2015;17:33.","journal-title":"Breast Cancer Res"},{"key":"908_CR288","doi-asserted-by":"publisher","first-page":"1453739","DOI":"10.1155\/2023\/1453739","volume":"2023","author":"S Wang","year":"2023","unstructured":"Wang S, Xia Y, Huang P, Xu C, Qian Y, Fang T, et al. Suppression of GCH1 sensitizes ovarian cancer and breast cancer to PARP inhibitor. J Oncol. 2023;2023:1453739.","journal-title":"J Oncol"},{"issue":"7","key":"908_CR289","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41419-024-06894-1","volume":"15","author":"M Chiappa","year":"2024","unstructured":"Chiappa M, Decio A, Guarrera L, Mengoli I, Karki A, Yemane D, et al. Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas. Cell Death Dis. 2024;15(7):521.","journal-title":"Cell Death Dis"},{"issue":"1","key":"908_CR290","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12964-025-02056-8","volume":"23","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Wu Y, Wang Q, Li M, Deng C, Gu X. Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair. Cell Commun Signal. 2025;23(1):48.","journal-title":"Cell Commun Signal"},{"issue":"12","key":"908_CR291","doi-asserted-by":"publisher","first-page":"101834","DOI":"10.1016\/j.xcrm.2024.101834","volume":"5","author":"S Awasthi","year":"2024","unstructured":"Awasthi S, Dobrolecki LE, Sallas C, Zhang X, Li Y, Khazaei S, et al. UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Rep. Med. 2024;5(12):101834.","journal-title":"Cell Rep. Med"},{"issue":"11","key":"908_CR292","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1111\/cas.14201","volume":"110","author":"L Zhao","year":"2019","unstructured":"Zhao L, Si CS, Yu Y, Lu JW, Zhuang Y. Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51. Cancer Sci. 2019;110(11):3543\u201352.","journal-title":"Cancer Sci"},{"issue":"37","key":"908_CR293","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1038\/s41388-023-02785-5","volume":"42","author":"U Ray","year":"2023","unstructured":"Ray U, Thirusangu P, Jin L, Xiao Y, Pathoulas CL, Staub J, et al. PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction. Oncogene. 2023;42(37):2725\u201336.","journal-title":"Oncogene"},{"key":"908_CR294","doi-asserted-by":"publisher","first-page":"217268","DOI":"10.1016\/j.canlet.2024.217268","volume":"604","author":"Z Luo","year":"2024","unstructured":"Luo Z, Huang Y, Chen S, Zhang B, Huang H, Dabiri S, et al. Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer. Cancer Lett. 2024;604:217268.","journal-title":"Cancer Lett"},{"issue":"6538","key":"908_CR295","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1126\/science.abb4542","volume":"372","author":"K Fugger","year":"2021","unstructured":"Fugger K, Bajrami I, Silva Dos Santos M, Young SJ, Kunzelmann S, Kelly G, et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science. 2021;372(6538):156\u201365.","journal-title":"Science"},{"issue":"6","key":"908_CR296","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/0008-5472.CAN-23-1908","volume":"84","author":"TT Huang","year":"2024","unstructured":"Huang TT, Chiang CY, Nair JR, Wilson KM, Cheng K, Lee JM. AKT1 interacts with DHX9 to mitigate R loop-induced replication stress in ovarian cancer. Cancer Res. 2024;84(6):887\u2013904.","journal-title":"Cancer Res"},{"issue":"5","key":"908_CR297","doi-asserted-by":"publisher","first-page":"114205","DOI":"10.1016\/j.celrep.2024.114205","volume":"43","author":"BR Hill","year":"2024","unstructured":"Hill BR, Ozgencil M, Buckley-Benbow L, Skingsley SLP, Tomlinson D, Eizmendi CO, et al. Loss of POLE3-POLE4 unleashes replicative gap accumulation upon treatment with PARP inhibitors. Cell Rep. 2024;43(5):114205.","journal-title":"Cell Rep"},{"issue":"20","key":"908_CR298","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1158\/0008-5472.CAN-24-0293","volume":"84","author":"L Cadzow","year":"2024","unstructured":"Cadzow L, Brenneman J, Tobin E, Sullivan P, Nayak S, Ali JA, et al. The USP1 inhibitor KSQ-4279 overcomes PARP inhibitor resistance in homologous recombination-deficient tumors. Cancer Res. 2024;84(20):3419\u201334.","journal-title":"Cancer Res"},{"issue":"20","key":"908_CR299","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1158\/0008-5472.CAN-23-4007","volume":"84","author":"da Costa Aa","year":"2024","unstructured":"da Costa Aa, Somuncu O, Ravindranathan R, Mukkavalli S, Martignetti DB, Nguyen H, et al. Single-stranded DNA gap accumulation is a functional biomarker for USP1 inhibitor sensitivity. Cancer Res. 2024;84(20):3435\u201346.","journal-title":"Cancer Res"},{"key":"908_CR300","doi-asserted-by":"crossref","unstructured":"Nespolo A, Stefenatti L, Pellarin I, Gambelli A, Rampioni Vinciguerra GL, Karimbayli J, et al. USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity. Sci Adv. 2024;10(46):eadp 6567.","DOI":"10.1126\/sciadv.adp6567"},{"issue":"1","key":"908_CR301","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/s41598-023-28454-x","volume":"13","author":"NA Yusoh","year":"2023","unstructured":"Yusoh NA, Chia SL, Saad N, Ahmad H, Gill MR. Synergy of ruthenium metallo-intercalator, [Ru(dppz)(2)(PIP)](2+), with PARP inhibitor olaparib in non-small cell lung cancer cells. Sci Rep. 2023;13(1):1456.","journal-title":"Sci Rep"},{"issue":"10","key":"908_CR302","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.1021\/acs.jmedchem.3c00322","volume":"66","author":"NA Yusoh","year":"2023","unstructured":"Yusoh NA, Tiley PR, James SD, Harun SN, Thomas JA, Saad N, et al. Discovery of Ruthenium(II) metallocompound and olaparib synergy for cancer combination therapy. J Med Chem. 2023;66(10):6922\u201337.","journal-title":"J Med Chem"},{"issue":"10","key":"908_CR303","doi-asserted-by":"publisher","first-page":"113307","DOI":"10.1016\/j.celrep.2023.113307","volume":"42","author":"Y Xu","year":"2023","unstructured":"Xu Y, Spear S, Ma Y, Lorentzen MP, Gruet M, McKinney F, et al. Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. Cell Rep. 2023;42(10):113307.","journal-title":"Cell Rep"},{"issue":"8065","key":"908_CR304","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s41586-025-08935-x","volume":"641","author":"D Chen","year":"2025","unstructured":"Chen D, Lu S, Huang K, Pearson JD, Pacal M, Peidis P, et al. Cell cycle duration determines oncogenic transformation capacity. Nature. 2025;641(8065):1309\u201318.","journal-title":"Nature"},{"issue":"15","key":"908_CR305","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","volume":"83","author":"V Garg","year":"2023","unstructured":"Garg V, Oza AM. Treatment of ovarian cancer beyond PARP inhibition: current and future options. Drugs. 2023;83(15):1365\u201385.","journal-title":"Drugs"},{"key":"908_CR306","doi-asserted-by":"crossref","unstructured":"Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, et al. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51. Sci Transl Med. 2019;11(492):eaav 4508.","DOI":"10.1126\/scitranslmed.aav4508"},{"issue":"19","key":"908_CR307","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.21.02011","volume":"40","author":"JF Liu","year":"2022","unstructured":"Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, et al. Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial. J Clin Oncol. 2022;40(19):2138\u201347.","journal-title":"J Clin Oncol"},{"issue":"11","key":"908_CR308","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","volume":"15","author":"JF Liu","year":"2014","unstructured":"Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. The Lancet Oncol. 2014;15(11):1207\u201314.","journal-title":"The Lancet Oncol"},{"issue":"7","key":"908_CR309","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.7150\/ijbs.91861","volume":"20","author":"M Wang","year":"2024","unstructured":"Wang M, Yuan C, Wu Z, Xu M, Chen Z, Yao J, et al. Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the ROR\u03b1\/ECM1\/VEGFR2 signaling axis. Int J Biol Sci. 2024;20(7):2454\u201375.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"908_CR310","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","volume":"15","author":"S Li","year":"2022","unstructured":"Li S, Wang L, Wang Y, Zhang C, Hong Z, Han Z. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment. J Hematol Oncol. 2022;15(1):147.","journal-title":"J Hematol Oncol"},{"issue":"20","key":"908_CR311","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","volume":"25","author":"K Parmar","year":"2019","unstructured":"Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, et al. The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition. Clin Cancer Res. 2019;25(20):6127\u201340.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"908_CR312","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11(1):3726.","journal-title":"Nat Commun"},{"issue":"12","key":"908_CR313","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, et al. Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor Regression in BRCA-Mutant ovarian cancer models. Clin Cancer Res. 2017;23(12):3097\u2013108.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"908_CR314","doi-asserted-by":"publisher","first-page":"167574","DOI":"10.1016\/j.bbadis.2024.167574","volume":"1871","author":"\u0141 Biega\u0142a","year":"2025","unstructured":"Biega\u0142a \u0141, Statkiewicz M, Gajek A, Szymczak-Pajor I, Rusetska N, \u015aliwi\u0144ska A, et al. Molecular mechanisms restoring olaparib efficacy through ATR\/CHK1 pathway inhibition in olaparib-resistant BRCA1\/2(MUT) ovarian cancer models. Biochim Biophys Acta Mol Basis Dis. 2025;1871(2):167574.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"23","key":"908_CR315","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","volume":"29","author":"A Ring","year":"2023","unstructured":"Ring A, Kilburn LS, Pearson A, Moretti L, Afshari-Mehr A, Wardley AM, et al. Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK\/15\/010). Clin Cancer Res. 2023;29(23):4751\u201359.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"908_CR316","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","volume":"163","author":"PD Shah","year":"2021","unstructured":"Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, et al. Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2021;163(2):246\u201353.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"908_CR317","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/cncr.35059","volume":"130","author":"S Park","year":"2024","unstructured":"Park S, Kim YJ, Min YJ, Mortimer PGS, Kim HJ, Smith SA, et al. Biomarker-driven phase 2 umbrella trial: clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. Cancer. 2024;130(4):541\u201352.","journal-title":"Cancer"},{"key":"908_CR318","doi-asserted-by":"publisher","first-page":"216820","DOI":"10.1016\/j.canlet.2024.216820","volume":"589","author":"E Orhan","year":"2024","unstructured":"Orhan E, Velazquez C, Tabet I, Fenou L, Rodier G, Orsetti B, et al. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in triple negative breast cancer. Cancer Lett. 2024;589:216820.","journal-title":"Cancer Lett"},{"issue":"2","key":"908_CR319","first-page":"55","volume":"9","author":"S Boussios","year":"2019","unstructured":"Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, et al. PARP inhibitors in ovarian cancer: the route to \u201cIthaca\u201d. Diagn (Basel). 2019;9(2):55.","journal-title":"Diagn (Basel)"},{"issue":"3","key":"908_CR320","doi-asserted-by":"publisher","first-page":"110261","DOI":"10.1016\/j.celrep.2021.110261","volume":"38","author":"CR Elb\u00e6k","year":"2022","unstructured":"Elb\u00e6k CR, Petrosius V, Benada J, Erichsen L, Damgaard RB, S\u00f8rensen CS. WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity. Cell Rep. 2022;38(3):110261.","journal-title":"Cell Rep"},{"issue":"20","key":"908_CR321","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1158\/1078-0432.CCR-22-0568","volume":"28","author":"V Serra","year":"2022","unstructured":"Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, et al. Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance. Clin Cancer Res. 2022;28(20):4536\u201350.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"908_CR322","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41523-023-00568-5","volume":"9","author":"ZL Teo","year":"2023","unstructured":"Teo ZL, O\u2019Connor MJ, Versaci S, Clarke KA, Brown ER, Percy LW, et al. Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1\/2 wildtype triple-negative breast cancer. NPJ Breast Cancer. 2023;9(1):68.","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"908_CR323","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","volume":"35","author":"Y Fang","year":"2019","unstructured":"Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, et al. Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy. Cancer Cell. 2019;35(6):851\u201367.","journal-title":"Cancer Cell"},{"issue":"19","key":"908_CR324","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1158\/1078-0432.CCR-14-1038","volume":"20","author":"D Karnak","year":"2014","unstructured":"Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, et al. Combined inhibition of Wee1 and PARP1\/2 for radiosensitization in pancreatic cancer. Clin Cancer Res. 2014;20(19):5085\u201396.","journal-title":"Clin Cancer Res"},{"key":"908_CR325","doi-asserted-by":"crossref","unstructured":"Bulanova D, Akimov Y, Senkowski W, Oikkonen J, Gall-Mas L, Timonen S, et al. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells. Sci Adv. 2024;10(21):eadj 1564.","DOI":"10.1126\/sciadv.adj1564"},{"key":"908_CR326","doi-asserted-by":"crossref","unstructured":"Liu S, Deng P, Yu Z, Hong JH, Gao J, Huang Y, et al. CDC7 inhibition potentiates antitumor efficacy of PARP inhibitor in advanced ovarian cancer. Adv Sci (Weinh). 2024;11(45):e2403782.","DOI":"10.1002\/advs.202403782"},{"key":"908_CR327","doi-asserted-by":"crossref","unstructured":"Kim C, Wang XD, Yu Y. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response. eLife. 2020;9:e60637.","DOI":"10.7554\/eLife.60637"},{"issue":"14","key":"908_CR328","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711\u201320.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"908_CR329","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, et al. PARP inhibition elicits STING-Dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018;25(11):2972\u201380.","journal-title":"Cell Rep"},{"issue":"6","key":"908_CR330","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via Intratumoral STING pathway activation in BRCA-Deficient models of triple-negative breast cancer. Cancer Discov. 2019;9(6):722\u201337.","journal-title":"Cancer Discov"},{"issue":"14","key":"908_CR331","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.3390\/ijerph19148577","volume":"19","author":"A Revythis","year":"2022","unstructured":"Revythis A, Limbu A, Mikropoulos C, Ghose A, Sanchez E, Sheriff M, et al. Recent insights into PARP and Immuno-checkpoint inhibitors in epithelial ovarian cancer. Int J Environ Res Public Health. 2022;19(14):8577.","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"16","key":"908_CR332","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","volume":"26","author":"EJ Lampert","year":"2020","unstructured":"Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26(16):4268\u201379.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"908_CR333","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/ijgc-2021-002593","volume":"31","author":"L Musacchio","year":"2021","unstructured":"Musacchio L, Salutari V, Pignata S, Braicu E, Cibula D, Colombo N, et al. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician\u2019s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). Int J Gynecol Cancer. 2021;31(10):1369\u201373.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"908_CR334","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1200\/JCO.22.00205","volume":"41","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Park SH, Kozlov V, Dao TV, Castellano D, Li JR, et al. Durvalumab plus olaparib in Previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: a multicenter, randomized, phase II trial (BAYOU). J Clin Oncol. 2023;41(1):43\u201353.","journal-title":"J Clin Oncol"},{"issue":"25","key":"908_CR335","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403\u201315.","journal-title":"N Engl J Med"},{"issue":"24","key":"908_CR336","doi-asserted-by":"publisher","first-page":"9851","DOI":"10.1073\/pnas.1101053108","volume":"108","author":"PM Krawczyk","year":"2011","unstructured":"Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA. 2011;108(24):9851\u201356.","journal-title":"Proc. Natl. Acad. Sci. U. S. A"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00908-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:03:38Z","timestamp":1775829818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00908-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":336,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["908"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00908-0","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}